Articles On Immutep (ASX:IMM)

Immutep Ltd (ASX: IMM) shares ended the week on a disappointing note. The small cap ASX biotechnology share fell 3% to finish the session at 33 cents. But its shares may not be trading at those levels for long if one leading broker is to be...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on prelimin...

Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, whic...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck In this week's Weekly Insights:-Mate, Where Have The Profits Gone?-Al...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Immutep (ASX:IMM) has released its annual report, detailing significant progress over the past year with its lead immunotherapy candidate eftilagimod alpha (efti). This drug is designed to activate the body’s immune system to better recogni...

  To register for Friday's webinar click here. Immutep Limited (ASX:IMM) has fully recruited participants for Part A of its Phase I study evaluating IMP761, a novel LAG-3 immunotherapy. The single-dose, placebo-controlled trial has been com...

With the gold price trading around record highs, a number of ASX 200 gold shares have been rallying strongly this year. This has seen the S&P/ASX All Ordinaries Gold index rise 22% since the start of the year. But if you thought you wer...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Cettire Ltd (ASX: CTT) shares are catching the eye with a very strong gain on Tuesday. At the time of writing, the ASX All Ordinaries stock is up 48% to $1.98. Though, the online luxury products retailer's shares remain down by 60% from the...

Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates. The incentive – worth €2,194,918 – was provided under t...

The ASX200 is expected to open 0.12% lower today, despite strong gains on Wall Street. Investors in Australia are awaiting the Reserve Bank of Australia's (RBA) announcement on interest rates, with a decision due later today.   In the U.S....

The ASX200 is set to open 0.12% lower today, despite strong performances on Wall Street, as Australian investors await a rate cut decision from the Reserve Bank (RBA) later today. In the US, all three major bourses were higher: the S&amp...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer. Peter Milios: I'm Peter Milios from the Finance News Network, and today we're talking with Immutep (ASX:IMM)....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.2% to 8,135.1 points. Four ASX shares that are failing to follow the market higher today are...

Good afternoon. The ASX200 has been up 0.42% at 8,134 points. The local bourse is very close to breaking its record of 8,148 set in August. The Aussie market has so far shrugged of a second assassination attempt on former President Trump...

‘Wheezo’ maker Respiri says a new US deal will help to propel the company to cash-flow break even by the end of the year Immutep reports further promising data from its head neck and shoulder cancer program Oncosil Medical targets the diff...

  Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD's KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial revealed a 31.0% overall response rate i...

ASX nears record high as Fed rate cut speculation grows Wall Street rallies ahead of Fed decision; Boeing and Adobe shares slide Another Donald Trump’s assassination attempt in the past few hours?   The ASX could hit a new all-time high o...

Copper stocks elevated to the S&P/ASX 200 and S&P/ASX 300 including Sandfire Resources and Capstone Copper Corp Radiopharmaceutical company Clarity Pharmaceuticals is among healthcare names elevated to the S&P/ASX 300 Newly lis...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Inoviq’s NEURO-NET validated for Parkinson’s disease Nyrada’s NYR-BI03 shows safety in rats; Phase I planned for late 2024 Immutep at ESMO: data on eftilagimod alpha will be presented   Inoviq’s NEURO-NET validated in Parkinson’s Inoviq (...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases. Peter Milios: I'm Peter Milios from the Finance News N...

  To register for Friday's webinar click here. Immutep (ASX:IMM) has initiated a Phase I clinical trial to evaluate the safety and efficacy of IMP761, a novel LAG-3 agonist antibody. IMP761 is designed to restore immune system balance by en...

In a potential game-changer for millions of people worldwide, Immutep (ASX:IMM; NASDAQ:IMMP) has initiated the first human trials of IMP761, a novel agonist LAG-3 antibody designed to treat autoimmune diseases. The commencement of this Phas...

ASX set to open higher, driven by easing inflation data in the US US PPI fell short of expectations, boosting hopes for a Fed rate cut Starbucks up 24pc, Nvidia up 7pc, and Avon filed for bankruptcy   The ASX is set to open sharply higher...

Immutep (ASX:IMM) has confirmed it’s dosed the first human patient with its LAG-3 based autoimmune drug candidate IMP761. LAG-3 – which stands for Lymphocyte Activation Gene 3 – is believed to be able to interfere with haywire T cells in...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The S&P/ASX 200 Index (ASX: XJO) endured a tough start to the trading week this Monday, continuing the market malaise we saw at the end of last week's trading. By the closing bell today, the A...

While the S&P/ASX 200 Index (ASX: XJO) faces a downturn, slipping 0.9% to 7,902.4 points, several ASX shares have managed to buck the trend and achieve impressive gains.  29Metals Ltd (ASX: 29M) stands out with its share price climbing...

ASX healthcare stock Immutep Ltd (ASX: IMM) is surging after the company released a market-sensitive announcement before the open on Monday. Immutep advised it had a successful meeting with the US Food and Drug Administration (FDA) regar...

Immutep receives FDA feedback for its TACTI-004 Phase III trial design for tackling non small-cell lung cancer Althea forms JV to enter the US cannabis beverage market Chimeric enrols first participant in a Phase 1/2 trial for its CHM CDH1...

Two S&P/ASX 200 Index (ASX: XJO) shares are managing to swim against the retreating tide today. At the time of writing, the benchmark Aussie index is down 0.8%, with many stocks catching headwinds out of both the United States and Chin...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Monday. In afternoon trade, the benchmark index is down 0.9% to 7,902.4 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are ri...

Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment. Today, the company announced positive feedback from the US Foo...

Most investors probably wouldn't relish the idea of buying an ASX share that has already fallen by 77%. The ASX is full of investors who love to 'buy the dip', of course. But there aren't too many investors who would regard a 77% share pric...

The ASX is set to fall when it opens Monday, following Wall Street’s losses Major tech stocks like Nvidia and CrowdStrike saw drops, while crude oil tumbled 3pc President Biden has ended his re-election bid   The ASX200 index is expected...

The ASX200 is set to fall 0.56% after another weak day of trading on US markets. On Friday, US Stocks experienced a second session of losses, with the S&P 500 and the Nasdaq dropping 0.7% and 0.8%, respectively, while the Dow Jones e...

Immutep has received regulatory clearance from the Netherlands for its Phase I clinical trial of IMP761 Alcidion nabs $4m contract in a long-term partnership with Hume Rural Health Alliance   Immutep has clearance for Phase 1 trial Immute...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has run out of steam and is on course to record a decline. At the time of writing, the benchmark index is down 0.2% to 8,002.9 points. Four ASX shares that are not letting that hold...

ASX 200 adds about 60 points after intraday record Nine of 11 sectors higher, IT weighed by US megatech losses Pearl Gull Iron pops on REE in Chile   Local markets surged on Friday following positivity overnight on Wall Street after so...

ASX AI stocks have caught a strong bid in 2024. The artificial intelligence domain has seen tremendous growth, spurred on by the meteoric rise of US tech giants like Nvidia Corp (NASDAQ: NVDA). One Australian tech company is also capturi...

The S&P/ASX 200 Index (ASX: XJO) is having another strong session and is on course to end the week with a big gain. At the time of writing, the benchmark index is up 0.85% to 7,957.3 points. Four ASX shares that are rising more than m...

  To register for today's webinar click here. Immutep (ASX:IMM) has announced positive results from Cohort B of the TACTI-003 Phase IIb trial: Eftilagimod alfa (efti) in combination with KEYTRUDA®. The results demonstrate efficacy as first-...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

  Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep’s latest clinical results. Key points: Efti in c...

Immutep Ltd (ASX: IMM) shares are ending the week with a bang. In morning trade, the ASX healthcare stock is up 25% to 37 cents. Why is this ASX healthcare stock rocketing? This clinical-stage biotechnology company's shares are taking off t...